BRCA1 and head and neck neoplasm: Although further studies are needed to in more detail investigate the mechanisms responsible for the phenylbutyrate-induced abrogation of the FA/BRCA pathway, BRCA1 down-regulation and cisplatin-sensitization, our study opens up the possibility that phenylbutyrate could be used to sensitize cisplatin-resistant head and neck tumors in a clinical setting.